Novel complement inhibitors show promise in managing breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria, according to analysis of clinical trials.

Hemolysis was the most commonly cited cause of transfusion-associated death during the 1976–1985 period 10 but has become one of the least common fatal complications of transfusion, with an ...

Mean hemoglobin concentration increased by 0.9 g/dL at 12 weeks of treatment with pociredir, from a baseline of 7.8 g/dL to 8.7 g/dL. Together with the observed decrease in reticulocyte counts, the ...

Hemolysis results in impaired intestinal microcirculation and intestinal epithelial cell injury. World Journal of Gastroenterology, 2011; 17 (2): 213 DOI: 10.3748/wjg.v17.i2.213 ...

To manage patients’ hemolysis, 68% (n = 13) underwent a dose increase of pegcetacoplan from twice weekly to 1080 mg every 3 days. This approach reportedly benefited 6 patients’ hemolytic outcomes.

Extensive hemolysis ensues, with jaundice, and often death from renal impairment associated with hemoglobinuria. The animal may survive the initial attack and suffer several further episodes.

Werfen today announced the expansion of commercialization for the GEM Premier 7000 with iQM3 blood gas testing system, following its success in North America. Building on strong clinical adoption and ...

More information: "Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions" Nature Immunology, DOI: 10.1038/ni.3590 ...

Clinical use of the DAT The DAT is useful in differentiating immune-mediated hemolysis from hemolysis caused by other factors (Box 1). It is important to note that a small but significant number of ...